Literature DB >> 29505759

Risk of Serious Infection, Opportunistic Infection, and Herpes Zoster among Patients with Psoriasis in the United Kingdom.

Junko Takeshita1, Daniel B Shin2, Alexis Ogdie3, Joel M Gelfand4.   

Abstract

The risk of infection among patients with psoriasis of varying severity in a broadly representative population remains poorly understood. Using The Health Improvement Network (THIN), an electronic medical records database representative of the general UK population, we performed a cohort study to determine the risks of serious infection, opportunistic infection, and herpes zoster among patients with versus without psoriasis and according to psoriasis severity. We identified 187,258 patients with mild and 12,442 patients with moderate to severe psoriasis based on treatment patterns. Using Cox proportional hazards regression, the adjusted hazard ratios (95% confidence intervals) for serious infection were 1.18 (1.16-1.21) and 1.63 (1.52-1.75) for the mild and moderate to severe psoriasis groups, respectively. Among a nested cohort of 8,569 psoriasis patients with disease severity classified by body surface area involvement, similar results were obtained with the exception of an attenuated but significantly increased risk of serious infection among the moderate to severe psoriasis group (1.27 [1.10-1.47]). Overall, the risks of opportunistic infection and herpes zoster were significantly increased only among the moderate to severe psoriasis group and were associated with immunosuppressive therapy. Our analyses suggest that psoriasis is associated with an increased risk of serious infection, and psoriasis severity is a predictor of serious infection risk.
Copyright © 2018 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29505759      PMCID: PMC6083876          DOI: 10.1016/j.jid.2018.01.039

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  33 in total

1.  Use of the UK General Practice Research Database for pharmacoepidemiology.

Authors:  L A García Rodríguez; S Pérez Gutthann
Journal:  Br J Clin Pharmacol       Date:  1998-05       Impact factor: 4.335

2.  Validation studies of the health improvement network (THIN) database for pharmacoepidemiology research.

Authors:  James D Lewis; Rita Schinnar; Warren B Bilker; Xingmei Wang; Brian L Strom
Journal:  Pharmacoepidemiol Drug Saf       Date:  2007-04       Impact factor: 2.890

3.  Increased risk of infectious disease requiring hospitalization among patients with psoriasis: a population-based cohort.

Authors:  Marlies Wakkee; Esther de Vries; Pieter van den Haak; Tamar Nijsten
Journal:  J Am Acad Dermatol       Date:  2011-06-12       Impact factor: 11.527

4.  Intraportal lipopolysaccharide suppresses pulmonary antibacterial defense mechanisms.

Authors:  C M Mason; E Dobard; W R Summer; S Nelson
Journal:  J Infect Dis       Date:  1997-11       Impact factor: 5.226

5.  The risk of stroke in patients with psoriasis.

Authors:  Joel M Gelfand; Erica D Dommasch; Daniel B Shin; Rahat S Azfar; Shanu K Kurd; Xingmei Wang; Andrea B Troxel
Journal:  J Invest Dermatol       Date:  2009-05-21       Impact factor: 8.551

6.  The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003-2004.

Authors:  Shanu Kohli Kurd; Joel M Gelfand
Journal:  J Am Acad Dermatol       Date:  2008-11-20       Impact factor: 11.527

7.  Psoriasis is associated with increased beta-defensin genomic copy number.

Authors:  Edward J Hollox; Ulrike Huffmeier; Patrick L J M Zeeuwen; Raquel Palla; Jesús Lascorz; Diana Rodijk-Olthuis; Peter C M van de Kerkhof; Heiko Traupe; Gys de Jongh; Martin den Heijer; André Reis; John A L Armour; Joost Schalkwijk
Journal:  Nat Genet       Date:  2007-12-02       Impact factor: 38.330

8.  Expanding the psoriasis disease profile: interrogation of the skin and serum of patients with moderate-to-severe psoriasis.

Authors:  Mayte Suárez-Fariñas; Katherine Li; Judilyn Fuentes-Duculan; Karen Hayden; Carrie Brodmerkel; James G Krueger
Journal:  J Invest Dermatol       Date:  2012-07-05       Impact factor: 8.551

9.  Risk of moderate to advanced kidney disease in patients with psoriasis: population based cohort study.

Authors:  Joy Wan; Shuwei Wang; Kevin Haynes; Michelle R Denburg; Daniel B Shin; Joel M Gelfand
Journal:  BMJ       Date:  2013-10-15

10.  Purposeful selection of variables in logistic regression.

Authors:  Zoran Bursac; C Heath Gauss; David Keith Williams; David W Hosmer
Journal:  Source Code Biol Med       Date:  2008-12-16
View more
  22 in total

Review 1.  In the Real World: Infections Associated with Biologic and Small Molecule Therapies in Psoriatic Arthritis and Psoriasis.

Authors:  Sarah A R Siegel; Kevin L Winthrop
Journal:  Curr Rheumatol Rep       Date:  2019-06-06       Impact factor: 4.592

2.  Racial Differences in Perceptions of Psoriasis Therapies: Implications for Racial Disparities in Psoriasis Treatment.

Authors:  Junko Takeshita; Whitney T Eriksen; Valerie T Raziano; Claire Bocage; Lynn Hur; Ruchi V Shah; Joel M Gelfand; Frances K Barg
Journal:  J Invest Dermatol       Date:  2019-02-06       Impact factor: 8.551

Review 3.  Psoriasis: Past, Present, and Future.

Authors:  Allison C Billi; Johann E Gudjonsson; John J Voorhees
Journal:  J Invest Dermatol       Date:  2019-11       Impact factor: 8.551

4.  Influenza Vaccination Rates in Adults with Psoriasis Compared to Adults with Other Chronic Diseases.

Authors:  Megan H Noe; Daniel B Shin; Rebecca A Hubbard; Sean Hennessy; Joel M Gelfand
Journal:  J Invest Dermatol       Date:  2018-10-10       Impact factor: 8.551

Review 5.  Roles of Infection in Psoriasis.

Authors:  Shihui Zhou; Zhirong Yao
Journal:  Int J Mol Sci       Date:  2022-06-23       Impact factor: 6.208

Review 6.  Epidemiology of Psoriasis and Comorbid Diseases: A Narrative Review.

Authors:  Jin Bu; Ruilian Ding; Liangjia Zhou; Xiangming Chen; Erxia Shen
Journal:  Front Immunol       Date:  2022-06-10       Impact factor: 8.786

7.  Risk of herpesvirus, serious and opportunistic infections in atopic dermatitis: a population-based cohort study.

Authors:  J Wan; D B Shin; M N Syed; K Abuabara; A R Lemeshow; J M Gelfand
Journal:  Br J Dermatol       Date:  2022-01-20       Impact factor: 11.113

8.  Long-term safety of risankizumab from 17 clinical trials in patients with moderate-to-severe plaque psoriasis.

Authors:  K B Gordon; M Lebwohl; K A Papp; H Bachelez; J J Wu; R G Langley; A Blauvelt; B Kaplan; M Shah; Y Zhao; R Sinvhal; K Reich
Journal:  Br J Dermatol       Date:  2021-11-24       Impact factor: 11.113

9.  Comparative risk of herpes zoster in patients with psoriatic disease on systemic treatments: a systematic review and network meta-analysis.

Authors:  Hsien-Yi Chiu; Yi-Teng Hung; Shi-Wei Huang; Yu-Huei Huang
Journal:  Ther Adv Chronic Dis       Date:  2022-05-02       Impact factor: 4.970

10.  Risk of Herpes Zoster Among Psoriasis Patients Taking Biologics: A Network Meta-Analysis of Cohort Studies.

Authors:  Zhenwei Tang; Minxue Shen; Xiang Chen
Journal:  Front Med (Lausanne)       Date:  2021-06-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.